Abstract

Anxiety and stress disorders are the most commonly occurring of all mental illnesses, and current treatments are less than satisfactory. So, the discovery of novel approaches to treat anxiety disorders remains an important area of neuroscience research. Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system, and G-protein-coupled metabotropic glutamate (mGlu) receptors function to regulate excitability via pre- and postsynaptic mechanisms. Various mGlu receptor subtypes, including group I (mGlu₁ and mGlu₅), group II (mGlu₂ and mGlu₃), and group III (mGlu₄, mGlu₇ and mGlu₈) receptors, specifically modulate excitability within crucial brain structures involved in anxiety states. In addition, agonists for group II (mGlu_2/3) receptors and antagonists for group I (in particular mGlu₅) receptors have shown activity in animal and/or human conditions of fear, anxiety or stress. These studies indicate that metabotropic glutamate receptors are interesting new targets to treat anxiety disorders in humans.

Author affiliations

1. Eli Lilly and Company, Neuroscience Division, Lilly Corporate Center DC 0510, Indianapolis, Indiana 46285, USA.

Correspondence to: Darryle D. Schoepp¹ Email: schoepp@lilly.com

Published online 24 January 2005

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.